The effect of estradiol valerate and dienogest combination on serum homocysteine levels in postmenopausal women: A clinical trial

References

• Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995; 38: 199–210
   PubMed Web of Science ®Google Scholar
• Grady D, Rubin S M, Petitti D B, Fox C S, Black D, Ettinger B, Ernster V L, Cummings S R. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992; 117: 1016–1037
   PubMed Web of Science ®Google Scholar
• Whitmer R A, Haan M N, Miller J W, Yaffe K. Hormone replacement therapy and cognitive performance: the role of homocysteine. J Gerontol A Biol Sci Med Sci. 2003; 58: 324–330
   Google Scholar
• Legault C, Stefanick M L, Miller V, Marcovina S M, Schrott H G. Effect of hormone replacement therapy on the validity of Friedwald equation in postmenopausal women: the postmenopausal estrogen/progestins interventions (PEPI) trial. J Clin Epidemiol 1999; 52: 1187–1195
   Google Scholar
• Shlipak M, Simon J, Vittinghoff E, Lin F, Barrett-Connor E, Knopp R H, Levy R I, Hulley S B. Estrogen and progestin, lipoprotein(a) and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283: 1845–1852
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Aronow W S, Ahn C, Gutstein H. Increased plasma homocysteine is an independent predictor of new atherothrombotic brain infarction in older persons. Am J Cardiol. 2000; 86: 585–586; A10
   Google Scholar
• Kittner S J, Giles W H, Macko R F, Hebel J R, Wozniak M A, Wityk R J, Stolley P D, Stern B J, Sloan M A, Sherwin R. Homocyst(e)ine and risk of cerebral infarction in a biracial population: the stroke prevention in young women study. Stroke 1999; 20: 1554–1560
   Google Scholar
• Brattström L E, Hultberg B L, Hardebo J E. Folic acid responsive postmenopausal homocysteinemia. Metabolism 1985; 34: 63–67
   Google Scholar
• Boers G H, Smals A G, Trijbels F J, Leermakers A I, Kloppenborg P W. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in reproductive years. J Clin Invest. 1983; 72: 1971–1976
   PubMedGoogle Scholar
• Kang S -S, Wong P WK, Cook H Y, Norusis M, Messer J V. Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease. J Clin Invest. 1986; 77: 1482–1486
   PubMed Web of Science ®Google Scholar
• Andersson A, Brattstöm L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender and post- menopausal status. Eur J Clin Invest. 1992; 22: 79–87
   PubMed Web of Science ®Google Scholar
• Dudman N PB, Wilcken D EL, Wang J, Lynch J F, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy and enzymology. Arterioscler Thromb 1993; 13: 1253–1260
   PubMedGoogle Scholar
• Million Women Study Collaborators, Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
   PubMed Web of Science ®Google Scholar
• Pines A, Bornstein N M, Shapira I. Menopause and ischaemic stroke: basic, clinical and epidemiological considerations. The role of hormone replacement. Hum Reprod Update 2002; 8: 161–168
   PubMedGoogle Scholar
• Spencer C P, Godsland I F, Stevenson J C. Is there a menopausal metabolic syndrome?. Gynecol Endocrinol 1997; 11: 341–355
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson J E, Colditz G A, Willett W C, Speizer F E, Stampfer M J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000; 133: 933–941
   PubMed Web of Science ®Google Scholar
• Simon J A, Hsia J, Cauley J A, Richards C, Harris F, Fong J, Barrett-Connor E, Hulley S B. Postmenopausal hormone use and the risk of stroke. The Heart and Estrogen–progestin Replacement Study HERS. Circulation 2001; 103: 638–642
   PubMed Web of Science ®Google Scholar
• Tolbert T, Oparil S. Hormone replacement therapy and stroke: are the results surprising?. Circulation 2001; 103: 620–622
   Google Scholar
• Paganini-Hill A. Hormone replecament therapy and stroke: risk, protection or no effect?. Maturitas 2001; 38: 243–261
   PubMed Web of Science ®Google Scholar
• American Heart Association, Mosca L, Collins P, Herrington D M, Mendelsohn M E, Pasternak R C, Robertson R M, Schenck-Gustafsson K, Smith S C, Jr, Taubert K A, Wenger N K. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104: 499–503
   Google Scholar
• Wellington K, Perry C M. Estradiol valerate/dionegest. Drugs 2002; 62: 491–504
   PubMed Web of Science ®Google Scholar
• Wouters M G, Moorrees M T, van der Mooren M J, Blom H J, Boers G H, Schellekens L A, Thomas C M, Eskes T K. Plasma homocysteine and postmenopausal status. Eur J Clin Invest. 1995; 25: 801–805
   PubMed Web of Science ®Google Scholar
• Obwegeser R, Hohlagschwandtner M, Sinzinger H. Homocysteine – a pathophysiological cornerstone in obstetrical and gynaecological disorders?. Hum Reprod Update 1999; 5: 64–72
   Google Scholar
• Christodoulakos G, Panoulis C, Rizos D, Moustakarias T, Phocas I, Creatsas G. Homocysteine and folate levels in postmenopausal women. Maturitas 2001; 39: 161–167
   PubMed Web of Science ®Google Scholar
• Van der Mooren M J, Demacker P N, Blom H J, de Rijke Y B, Rolland R. The effect of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in post menopausal women. Fertil Steril. 1997; 67: 67–73
   PubMed Web of Science ®Google Scholar
• Walsh B W, Paul S, Wild R A, Dean R A, Tracy R P, Cox D A, Anderson P W. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2000; 65: 214–218
   Google Scholar
• Hak A E, Bak A A, Lindemans J, Planellas J, Coelingh Bennink H J, Hofman A, Grobbee D E, Witteman J C. The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled trial. Atherosclerosis 2001; 158: 437–443
   PubMed Web of Science ®Google Scholar
• Barnabei V M, Phillips T M, Hsia J. Plasma homocysteine in women taking hormone replecament therapy: The Postmenopausal Estrogen/progestin Interventions (PEPI) trial. J Womens Health Gend Based Med. 1999; 8: 1167–1172
   PubMedGoogle Scholar